GRCL - Gracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART™ Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting | Benzinga
Novel, proprietary technology designed to strengthen the functionality of CAR-T cells against solid tumors
SMART CAR-T cells demonstrated resistance to immunosuppressive tumor microenvironment (TME) and maintained long-term proliferation and cytotoxicity both in vitro and in vivo
Launching investigator-initiated trial (IIT) of SMART CART GC506 targeting Claudin 18.2 positive tumors
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (("Gracell" or the "Company", NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, announced today preclinical data from the Company's SMART CART™* technology for solid tumors will be presented as a poster at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place November 1-5, 2023, in San Diego and online.
"Gracell has long been dedicated to unlocking the tremendous potential of CAR-T therapy against solid tumors in our pursuit of transformative cell therapies. We are thrilled to present the encouraging preclinical data from SMART CART, our next-generation solid tumor technology," said Dr. Lianjun Shen, Gracell's Senior Vice President, Head of Research & Development. "Immunosuppressive tumor microenvironment is a known challenge that limits CAR-T cell proliferation and persistence, and, ultimately, its effectiveness against solid tumors. We believe our research to be presented at SITC demonstrates SMART CART's improved resistance to TME and superior in vitro and in vivo preclinical efficacy. We look forward to advancing the clinical IIT evaluating SMART CART GC506 for the treatment of Claudin 18.2 positive tumors, building upon the success we have seen with Gracell's work in hematologic cancers."
SMART CART is Gracell's next generation CAR-T technology against solid tumors, designed to enhance CAR-T cell proliferation and ...